In8bio Inc (INAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.86M
Last updated: Nov 17, 2026 at 11:04 AM ET
In8bio Inc (INAB) Competitors
The companies most similar to In8bio are GT Biopharma (GTBP), Intensity Therapeutics, Inc. Common stock (INTS) and Exicure (XCUR). By market cap, In8bio ranks 5th of the 13 companies on this page; Passage Bio (PASG) is the largest at $13.68M.
Peer Comparison
INAB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| In8bio (INAB) | $8.86M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Exicure Inc (XCUR) | $7.07M | N/A | N/A | 0.0% | N/A | 928.0% | 0.00% |
| Soligenix Inc. (SNGX) | $7.50M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| FibroBiologics, Inc. Common Stock (FBLG) | $6.57M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theriva Biologics Inc. (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| Passage Bio Inc (PASG) | $13.68M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Alaunos Therapeutics Inc (TCRT) | $6.86M | N/A | N/A | 0.0% | N/A | -25.0% | 0.00% |
| Peer median | $7.65M | N/A | 19.0x | 0.0% | -72.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to In8bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Exicure Inc (XCUR) | Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases... | XCUR competitors |
| Soligenix Inc. (SNGX) | Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. | SNGX competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| FibroBiologics, Inc. Common Stock (FBLG) | FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology... | FBLG competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Theriva Biologics Inc. (TOVX) | Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need. | TOVX competitors |
| Passage Bio Inc (PASG) | Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. | PASG competitors |
| Alaunos Therapeutics Inc (TCRT) | Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring... | TCRT competitors |
Frequently Asked Questions About INAB
Who are In8bio's main competitors?
The companies most similar to In8bio include GT Biopharma (GTBP), Intensity Therapeutics, Inc. Common stock (INTS), Exicure (XCUR), Soligenix (SNGX) and Moleculin Biotech (MBRX), listed from the closest match.
Who is In8bio's biggest competitor?
Passage Bio (PASG) is the largest of the similar companies at $13.68M; GT Biopharma (GTBP) is the closest match by business profile, size, sector and industry.
How does INAB stock compare with its competitors?
INAB's net margin is 0.0% against a peer median of 0.0%.
Which of In8bio's competitors pays a higher dividend?
In8bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is In8bio bigger than its competitors?
No. In8bio is 5th by market cap among the 13 companies on this page; the largest is Passage Bio (PASG) at $13.68M.
INAB pages: Overview, Earnings, Forecast, Financials, Competitors